Creso Pharma Limited announced that its Co-founder and Chief Executive Officer, Dr. Miri Halperin Wernli will transition to the role of Technology, Innovation and Distribution head and continue to serve on the Company's Board of Directors. Transitioning to the role of Technology, Innovation and Distribution head will allow Dr. Halperin Wernli to focus on new technologies for the hemp and cannabis products globally as well as on furthering the commercialization and distribution efforts of the Mernova medical cannabis products. Additional Board changes include Mr. Boaz Watchel moving from the role of Executive Chairman to Non-Executive Director. Mr. Adam Blumenthal will move from a Non-Executive Director to assume the position of Non- Executive Chairman, and Dr. James Ellingford will move from a Non-Executive Director to the role of Executive Director. The Company has also made key internal appointments within its Swiss International Operations division, with Mr. Jorge Wernli and Dr. Gian Trepp appointed to executive management positions. Both Mr. Wernli and Dr. Trepp are highly experienced in both the pharmaceutical and hemp/cannabis sector and will report directly to the Board of Directors.